+

WO1999037777A3 - Sequences associees a une differentiation et methodes d'utilisation - Google Patents

Sequences associees a une differentiation et methodes d'utilisation Download PDF

Info

Publication number
WO1999037777A3
WO1999037777A3 PCT/US1999/001624 US9901624W WO9937777A3 WO 1999037777 A3 WO1999037777 A3 WO 1999037777A3 US 9901624 W US9901624 W US 9901624W WO 9937777 A3 WO9937777 A3 WO 9937777A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
differentiation
polypeptides
polynucleotides
cancer therapy
Prior art date
Application number
PCT/US1999/001624
Other languages
English (en)
Other versions
WO1999037777A2 (fr
Inventor
Fei Huang
Paul B Fisher
Neil I Goldstein
Original Assignee
Genquest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genquest Inc filed Critical Genquest Inc
Priority to AU23433/99A priority Critical patent/AU2343399A/en
Publication of WO1999037777A2 publication Critical patent/WO1999037777A2/fr
Publication of WO1999037777A3 publication Critical patent/WO1999037777A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention a trait à des compositions ainsi qu'aux méthodes afférentes visant à inhiber la croissance cellulaire et à provoquer une différentiation terminale. Ces compositions sont également destinées à intervenir dans le cadre d'une thérapie anticancéreuse. Ces composés sont, en l'occurrence, des polypeptides et des polynucléotides associés à une différentiation terminale et à un arrêt de la croissance, ainsi que des polynucléotides codant ces polypeptides. L'invention, qui concerne également des vaccins et des compositions pharmaceutiques renfermant ces composés, porte, de surcroît, sur leur utilisation en matière de thérapie anticancéreuse. On peut aussi utiliser ces molécules pour identifier, notamment, des agents susceptibles d'entrer dans la formulation de vaccins et de compositions pharmaceutiques aux fins d'une thérapie anticancéreuse. Les polypeptides et les polynucléotides de l'invention peuvent, en outre, être utilisés comme marqueurs permettant de diagnostiquer un cancer chez un patient et de surveiller son évolution.
PCT/US1999/001624 1998-01-26 1999-01-26 Sequences associees a une differentiation et methodes d'utilisation WO1999037777A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23433/99A AU2343399A (en) 1998-01-26 1999-01-26 Differentiation-associated sequences and methods of use therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7252498P 1998-01-26 1998-01-26
US60/072,524 1998-01-26
US8465098P 1998-05-07 1998-05-07
US60/084,650 1998-05-07

Publications (2)

Publication Number Publication Date
WO1999037777A2 WO1999037777A2 (fr) 1999-07-29
WO1999037777A3 true WO1999037777A3 (fr) 1999-09-30

Family

ID=26753455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001624 WO1999037777A2 (fr) 1998-01-26 1999-01-26 Sequences associees a une differentiation et methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU2343399A (fr)
WO (1) WO1999037777A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (fr) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York PROCEDE DE CONSTITUTION D'UNE BANQUE D'ADNc A SOUSTRACTION ET UTILISATION DE LADITE BANQUE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (fr) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York PROCEDE DE CONSTITUTION D'UNE BANQUE D'ADNc A SOUSTRACTION ET UTILISATION DE LADITE BANQUE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Cloning a cDNA from human NK/T cells which codes for a protein with high proline content", BIOCHIM BIOPHYS ACTA, vol. 1264, no. 1, 17 October 1995 (1995-10-17), pages 19 - 22, XP002108017 *
DATABASE EMEST 15 E.M.B.L. Databases; 4 June 1997 (1997-06-04), HILLIER L ET AL: "Homo sapiens cDNA clone 758808 5' similar to TR:G476095 B4-2 protein", XP002108018 *
H JIANG AND P B FISHER: "Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells", MOLECULAR AND CELLULAR DIFFERENTIATION, vol. 3, no. 1, 1 July 1993 (1993-07-01), pages 285 - 289, XP002078760 *
H JIANG ET AL: "A molecular definition of terminal cell differentiation in human melanoma cells", MOLECULAR AND CELLULAR DIFFERENTIATION, vol. 2, no. 3, 1 July 1994 (1994-07-01), pages 221 - 239, XP002078944 *

Also Published As

Publication number Publication date
AU2343399A (en) 1999-08-09
WO1999037777A2 (fr) 1999-07-29

Similar Documents

Publication Publication Date Title
EP1876241A3 (fr) Compositions et procédés pour le traitement et le diagnostic du cancer du sein
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
CA2006473A1 (fr) Traitement antiinfectieux ameliore
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EP1420009A3 (fr) Nouveaux dérivés d'acides amines présentant une meilleure activité contre la résistance à plusieurs médicaments
SE9502167D0 (sv) Insulinanalog-kompositioner
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
IL148870A0 (en) 2'-substituted 1, 1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
EP1964850A3 (fr) Compositions thérapeutiques et diagnostiques du carcinome mammaire et méthodes afférentes
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
WO2001079276A3 (fr) Antigenes de la leishmania servant au traitement et au diagnostic de la leishmaniose
PL308074A1 (en) Derivatives of borone peptides, their production as well as their application in medical therapy
BG101126A (en) The use of muramylpeptide compounds
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO1999037774A3 (fr) Sequences associees a la differenciation cellulaire et procedes d'utilisation de ces sequences
WO1998035045A3 (fr) Antigenes leishmania utilises dans le traitement et le diagnostic de la leishmaniose
RU96119472A (ru) Ирригационный раствор для офтальмологии
WO1999037777A3 (fr) Sequences associees a une differentiation et methodes d'utilisation
WO1999060124A3 (fr) Sequences liees a la differenciation et procede d'utilisation correspondant
FI871545A7 (fi) Menetelmä syövän hoitoon käytettävän synergistisen seoksen valmistamiseksi, joka sisältää interleukiini-2:ta ja/tai interferoni- :aa ja kasvainnekroositekijää.
EP1574507A3 (fr) Furo- et pyranno-naphthoquinones et leur utilisation contre le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载